PharmiWeb.com - Global Pharma News & Resources
27-Sep-2024

CD Genomics Launches PacBio SMRT Sequencing Services to Revolutionize Genomic Research

 

CD Genomics, a leading provider of genomic services, is excited to announce the launch of its PacBio Single Molecule, Real-Time (SMRT) Sequencing service. This cutting-edge technology is set to transform genomic research by providing researchers with unprecedented access to long-read sequencing capabilities, enabling them to unlock the complexities of genomes like never before.

 

PacBio SMRT Sequencing stands out in the field of genomics due to its ability to generate exceptionally long reads, often exceeding 20 kilobases. This capability allows for the resolution of complex genomic regions, including repetitive sequences and structural variations, which are often challenging for traditional short-read sequencing methods. By utilizing circular consensus sequencing (CCS), PacBio technology ensures high accuracy, with error rates as low as 0.1%, making it an ideal choice for applications such as de novo genome assembly, structural variation detection, and the identification of epigenetic modifications.

 

“PacBio SMRT Sequencing represents a significant advancement in genomic technology,” said the Senior Scientist at CD Genomics. “Our commitment to providing the highest quality genomic data is reinforced by the integration of this powerful platform into our service offerings. We are excited to support researchers in their quest for deeper insights into the genomic landscape.”

 

The versatility of PacBio SMRT Sequencing allows it to cater to a wide range of applications, from targeted sequencing projects to large-scale whole-genome studies. This flexibility enables researchers to customize their sequencing strategies to meet specific project requirements, enhancing both efficiency and cost-effectiveness. Whether researchers are studying complex plant genomes, investigating human disease, or exploring microbial diversity, PacBio SMRT Sequencing provides the tools necessary to achieve their goals.

 

In addition to its technical capabilities, PacBio SMRT Sequencing offers significant advantages in terms of data analysis. The long reads generated by this technology facilitate the assembly of complex genomes, allowing researchers to construct more complete and accurate genomic maps. This is particularly important for organisms with large and repetitive genomes, where traditional short-read methods often fall short. Furthermore, the high accuracy of PacBio data reduces the need for extensive post-sequencing corrections, streamlining the analysis process and accelerating research timelines.

 

CD Genomics is dedicated to delivering exceptional service and support to its clients. With a team of experienced scientists and bioinformaticians, the company ensures that researchers receive personalized assistance throughout their projects, maximizing the potential of PacBio SMRT Sequencing technology. Clients can expect comprehensive support, from experimental design to data interpretation, ensuring that they can leverage the full power of this innovative technology.

 

“By integrating PacBio SMRT Sequencing into our offerings, we are not only enhancing our service portfolio but also empowering researchers to push the boundaries of genomic exploration,” added the senior scientist. “We believe this technology will play a crucial role in advancing our understanding of complex biological systems and driving innovation in genomics.”

 

About CD Genomics

CD Genomics is a premier provider of genomic services, offering a comprehensive range of solutions including next-generation sequencing, bioinformatics analysis, and custom genomics services. With a commitment to innovation and quality, CD Genomics empowers researchers to advance their scientific discoveries and contribute to the future of genomics.

 

Contact

Address: Shirley, NY 11967, USA

Email: contact@cd-genomics.com

Editor Details

Last Updated: 27-Sep-2024